Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Look to Supplier Stocks for an Obamacare Trade

By Michael Shulman, Editor, Options Income Blueprint
Wall Street hasn't paid much attention to Questcor (QCOR), a drug company with patients that could be moving to Medicaid in droves.

Roche’s Breast Cancer Drug Approval Is Just the Beginning

By James Brumley, InvestorPlace Feature Writer
It might have been dismissed as irrelevant by most investors, but Roche and its Perjeta could reshape the breast cancer drug landscape.

5 Stocks Leading the Generic Drug Charge

By James Brumley, InvestorPlace Feature Writer
As pervasive as generic drug usage has already become, experts say there's still lots of room to grow. These companies are leading that charge.

Bull’s Eye Report: Parexel (PRXL)

By Dave Moenning, Proprietor of StateoftheMarkets.com
Parexel is one of the best opportunities in pharma right now.

3 Pharma Stocks Just Running in Place

By Lawrence Meyers, InvestorPlace Contributor
Gobs of free cash flow doesn't mean a company is worth buying. Some companies, especially pharmaceuticals, just use cash to run in place.

Will MannKind’s Luck Change the Second Time Around?

By James Brumley, InvestorPlace Feature Writer
MannKind's diabetes drug, Afrezza, is back in Phase 3 trials and is showing similar promise. But can it clear the hump to approval ... unlike last time?

Pfizer & Merck: Dividend Winners or Duds?

By Dan Burrows, InvestorPlace Feature Writer
Pfizer and Merck got addicted to Lipitor and Singulair, and now slumping sales of the former blockbusters have both companies scrambling for growth.

5 Megatrend Plays Offering Big Payouts

By Alyssa Oursler, InvestorPlace Contributor
Megatrend investments usually require years if not decades to play out, but these five particular stocks offer investors some sizable income for waiting.

If Not Amgen, Who’s Next in Line to Buy Onyx?

By James Brumley, InvestorPlace Feature Writer
A few larger players could make attractive suitors for Onyx Pharmaceuticals and its cancer drugs, but the key is whether they'll trump an already frothy bid

3 Ways to Trade Diabetes Treatment

By Will Ashworth, InvestorPlace Contributor
The treatment of diabetes continues to be a huge boon to drug companies. Here is a look att three potential stock picks for the space.

Arena, Vivus Look Good (And It Has Nothing to Do With the AMA)

By James Brumley, InvestorPlace Feature Writer
The AMA has ruled to classify obesity more intensely -- as a "disease." But are ARNA and VVUS investors justified in being excited?

Now That Obesity Is Classified as a ‘Disease’ …

By Christopher Freeburn, InvestorPlace Writer
The American Medical Association's decision to classify obesity as a disease will impact physicians, patients, insurers and pharmaceutical companies.

It’s Hard to Win the Pharma News Game

By James Brumley, InvestorPlace Feature Writer
Big news for three cancer-treatment drugs had virtually zero effect on the stocks. Here's why investors shouldn't have been surprised, and what they can learn.

Pharma, Tech Drive the Dow: Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
markets managed to start out the new month on a up note, as pharmaceuticals and technology companies shined during a broad-based rally

Study: New Bird Flu Resistant to Roche’s Tamiflu

By Christopher Freeburn, InvestorPlace Writer
Physicians in China have noted that some patients with bird flu are not responding to treatment with Tamiflu, the only known drug used to fight the infection.

AstraZeneca to Purchase Omthera

By Marc Bastow, InvestorPlace Assistant Editor
AstraZeneca will purchase Omertha, a make of fish-oil based pharmaceuticals as it continues to bolster its cardiovascular product lineup

2 Stocks to Buy, 2 to Sell in Big Pharma

By Will Ashworth, InvestorPlace Contributor
Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries.

Should I Buy Pfizer? 3 Pros, 3 Cons

By Tom Taulli, InvestorPlace Contributor
Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore.

Belviq Is Not the Next Fen-Phen … Probably

By James Brumley, InvestorPlace Feature Writer
Arena Pharmaceuticals' withdrawal of its European application for Belviq has turned the stock into a three-ring circus. Don't panic -- just get the facts straight.
Load More